On the “niche watch list” of neuropeptide research, DSIP (δ-sleep-inducing peptide, CAS 62568-57-4) is a classic example of a substance whose name doesn’t quite live up to its reputation—in 1977, a Swiss team isolated this 9-amino acid peptide from rabbit cerebral venous blood. While its name is anchored in “sleep induction,” half a century later, the scope of research on it has long moved beyond a single function, transforming it into a “multi-faceted enigma” spanning sleep regulation and neural activity.
A 1985 cat experiment published in *Arch Int Physiol Biochim* cast the first doubt on its “sleep label”: After intracerebral injection of DSIP (7 nmol/kg) into cats deprived of REM sleep for 72 hours, total sleep time remained unchanged, but wakefulness and light slow-wave sleep (S1) were significantly reduced, while deep slow-wave sleep (S2) increased markedly; even the latencies to first entry into S2 and REM sleep were not prolonged. The researchers’ conclusion was objective: it did not directly promote sleep but merely adjusted sleep architecture during periods of peak sleep pressure (PMID:2421663).
Its neuromodulatory capabilities are even more “targeted.” A 2013 experiment on rats found that DSIP can “differentially regulate” dorsal hippocampal neurons in individuals with different stress resistance profiles: After stimulating the positive and negative emotional centers in active (highly stress-resistant) and passive (stress-susceptible) rats, respectively, DSIP reduced the neuronal responses of both groups to the positive emotional center, while making the active rats more sensitive to stimulation of the negative emotional center and the passive rats less responsive (PMID:24450167). This suggests that it may act as a “precision fine-tuner” of activity in emotion-related brain regions.
However, the core controversy surrounding DSIP was directly addressed in a 2006 review in *J Neurochem*: although it is called “sleep-inducing peptide,” no corresponding gene, protein, or receptor has been identified to date, and the evidence for its own sleep-promoting effects is extremely weak. In contrast, synthetically produced structural analogs have demonstrated clear slow-wave sleep-promoting activity in rabbits and rats. Its natural form and true core biological activity remain unclear to this day (PMID:16539679).
From modulating sleep architecture to regulating emotional neurons, every “functional clue” associated with this small-molecule peptide—with a molecular weight of 848.81—carries a footnote reading “to be verified.” Yet it is precisely these “unresolved mysteries” in scientific research that hold the greatest appeal—after all, today’s “ambiguity” may well be the gateway to tomorrow’s new directions in neuromodulation.